There is evidence that PD-L1 is expressed in EGFR-drivenNSCLC,31−33 and recently, it was also reported that PD-L1 isexpressed in sEVs from H1975 cells prior to EGFR-TKI treatment, andit was suggested that PD-L1 plays a role to circumvent immune systemattack.34 Earlier results have also shownthat EGFR-TKI influences PD-L1 expression in EGFR-mutant NSCLC cells.35 Therefore, in this study, we focused on EGFRand PD-L1 on sEVs from H1975 cells prior and post erlotinib and osimertinibtreatment using our improved sensing method. This evidence concerns the gene EGFR and non-small cell lung carcinoma.